Khullar Pooja, Garg Charu, Sinha Sujit Nath, Kaur Inderjit, Datta Niloy Ranjan
Department of Radiation Oncology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India.
Department of Radiation Oncology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India.
Med Dosim. 2018;43(4):370-376. doi: 10.1016/j.meddos.2017.12.001. Epub 2018 Jan 17.
An in silico dosimetric evaluation of intensity-modulated radiation therapy (IMRT) vs 3-dimensional conventional radiation therapy (3D-CRT) treatment plans in postmastectomy radiation therapy (PMRT) to the chest wall and regional lymphatics was conducted. Twenty-five consecutive patients with breast cancer referred for locoregional PMRT, stages T with N, were planned to receive 50 Gy in 25 fractions with IMRT. Additionally, a 3D-CRT plan was generated using identical contours for the clinical target volumes (CTV), planning target volumes (PTV), and organs at risk (OAR). Treatment plans were assessed using dose-volume histogram (DVH) parameters of D, D, D, D, and homogeneity index for individual CTVs and PTVs. OARs evaluated were ipsilateral and contralateral lungs, heart, spinal cord, and opposite breast. Most DVH parameters pertaining to CTVs and PTVs significantly favored IMRT. V for ipsilateral and contralateral lungs, D of heart and maximum dose to spinal cord favored IMRT (all p < 0.001). The mean dose to the opposite breast was significantly lesser with 3D-CRT (5.8 ± 1.8 Gy vs 2.0 ± 1.0 Gy, p < 0.001). Thus, except for the mean dose to the opposite breast, the compliance to DVH constraints applied to PTV and OARs were significantly better with IMRT. At a median follow-up of 76 months (7-91), none had locoregional failure or pulmonary or cardiac morbidity. For PMRT, requiring comprehensive irradiation to both chest wall and regional lymphatics, IMRT offers superior dosimetric advantages over 3D-CRT. This was also corroborated by long-term outcomes in these patients treated with IMRT.
对乳腺癌改良根治术后胸壁和区域淋巴结调强放射治疗(IMRT)与三维传统放射治疗(3D-CRT)治疗计划进行了计算机模拟剂量学评估。连续25例局部区域乳腺癌改良根治术患者(T分期伴N分期)计划接受IMRT,25次分割,总剂量50 Gy。此外,使用相同的临床靶区(CTV)、计划靶区(PTV)和危及器官(OAR)轮廓生成3D-CRT计划。使用个体CTV和PTV的剂量体积直方图(DVH)参数D、D、D、D和均匀性指数评估治疗计划。评估的OAR包括同侧和对侧肺、心脏、脊髓和对侧乳腺。大多数与CTV和PTV相关的DVH参数显著有利于IMRT。同侧和对侧肺的V、心脏的D和脊髓的最大剂量有利于IMRT(所有p<0.001)。3D-CRT时对侧乳腺的平均剂量显著更低(5.8±1.8 Gy对2.0±1.0 Gy,p<0.001)。因此,除对侧乳腺的平均剂量外,IMRT对PTV和OAR应用DVH约束的符合度显著更好。在中位随访76个月(7-91个月)时,无患者出现局部区域复发或肺部或心脏并发症。对于需要对胸壁和区域淋巴结进行全面照射的乳腺癌改良根治术后放疗,IMRT比3D-CRT具有更好的剂量学优势。这些接受IMRT治疗患者的长期结果也证实了这一点。